Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The variability of asthma.

Kevin R Murphy1, William E Berger

  • 1Midwest Children's Chest Physicians, Omaha, NE 68130, USA. murphknsc@aol.com

Current Medical Research and Opinion
|October 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asthma Impairment and Risk Questionnaire predicts short- and long-term exacerbation occurrence across asthma severities.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Efficacy and safety of as-needed albuterol-budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trial.

BMJ open respiratory research·2026
Same author

What is the Asthma Impairment and Risk Questionnaire and how can it help patients with asthma? A plain language summary of publications.

Therapeutic advances in respiratory disease·2025
Same author

Authors' response.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same author

Pediatric Asthma Impairment and Risk Questionnaire: A Control Assessment for Children Aged 5 to 11 Years.

The journal of allergy and clinical immunology. In practice·2025
Same author

Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study).

The journal of allergy and clinical immunology. In practice·2025

Asthma is a chronic airway inflammation affecting all ages. Tailoring inhaled corticosteroid therapy based on severity fluctuations can optimize asthma control and minimize medication needs.

Area of Science:

  • Pulmonology
  • Allergy and Immunology
  • Clinical Medicine

Background:

  • Asthma is a prevalent chronic airway inflammatory disease impacting all age groups.
  • Despite established treatment guidelines and effective medications, asthma morbidity persists, posing a significant socioeconomic burden.
  • Asthma severity varies from intermittent to persistent (mild, moderate, severe) and can fluctuate due to multiple factors.

Purpose of the Study:

  • To review the factors influencing asthma severity.
  • To emphasize the role of inhaled corticosteroids (ICSs) in managing persistent asthma.
  • To highlight the importance of adjusting ICS therapy based on episodic changes in asthma severity.

Main Methods:

  • This review synthesizes current knowledge on asthma pathophysiology, classification, and management.

Related Experiment Videos

  • It examines the evidence supporting inhaled corticosteroids (ICSs) as the preferred long-term controller therapy.
  • The review discusses factors contributing to asthma severity fluctuations and their impact on treatment.

    • Main Results:

    • Inhaled corticosteroids (ICSs) are demonstrated to be safe, well-tolerated, and effective for persistent asthma in all age groups.
    • Physiologic, environmental, socioeconomic, and behavioral factors can cause short-term and long-term fluctuations in asthma severity.
    • Optimal asthma control with minimal medication is achievable through awareness of severity changes and tailored ICS adjustments.

    Conclusions:

    • Persistent asthma requires long-term management with inhaled corticosteroids (ICSs) for all severities.
    • Monitoring and adapting ICS therapy in response to episodic asthma severity changes are crucial for effective disease control.
    • A proactive approach to asthma management, including individualized ICS adjustments, can lead to better patient outcomes and reduced healthcare burden.